Study of SB-BCLmR-HSPC (BCL11A Enhancer approach) for treatment of transfusion-dependent beta-thalassemia major
Phase of Trial: Phase I/II
Latest Information Update: 02 Oct 2017
At a glance
- Drugs SB-BCLmR-HSPC (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sangamo Therapeutics
- 02 Oct 2017 According to a Sangamo Therapeutics media release, this trial is expected to begin in the first half of 2018.
- 02 Oct 2017 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2018, according to a Sangamo Therapeutics media release.
- 02 Oct 2017 According to a Sangamo Therapeutics media release, the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application.